ProAxsis
1 known investors
ProAxsis develops active protease biomarker assays and a point-of-use test based on its patented ProteaseTag technology, along with specialist sample testing and scientific collaboration services. It serves pharmaceutical, biotech and academic research organisations conducting drug development and clinical trials, with a focus on respiratory and chronic lung diseases, inflammation and other protease-associated conditions.
Investors · 1
In the news
Frequently asked questions
- What does ProAxsis do?
- ProAxsis develops active protease biomarker assays and a point-of-use test based on its patented ProteaseTag technology, along with specialist sample testing and scientific collaboration services. It serves pharmaceutical, biotech and academic research organisations conducting drug development and clinical trials, with a focus on respiratory and chronic lung diseases, inflammation and other protease-associated conditions.
- Who are ProAxsis's investors?
- ProAxsis's investors include EMV Capital.